Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.51
(-0.79%)
HKD 2.51
(-0.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 160.52 Million CNY | -10.56% |
| 2022 | 214.8 Million CNY | -23.06% |
| 2021 | 277.82 Million CNY | 12.54% |
| 2020 | 235.91 Million CNY | -29.35% |
| 2019 | 309.28 Million CNY | 57.49% |
| 2018 | 157.08 Million CNY | 70.87% |
| 2017 | 119.18 Million CNY | -35.92% |
| 2016 | 185.01 Million CNY | 2.1% |
| 2015 | 181.37 Million CNY | 17.23% |
| 2014 | 154.36 Million CNY | 29.48% |
| 2013 | 119.22 Million CNY | 63.84% |
| 2012 | 73.65 Million CNY | 54.98% |
| 2011 | 47.84 Million CNY | 220.35% |
| 2010 | 14.65 Million CNY | 5692.89% |
| 2009 | 253 Thousand CNY | 101.63% |
| 2008 | -15.47 Million CNY | 27.08% |
| 2007 | -20.83 Million CNY | -39.86% |
| 2006 | -15.17 Million CNY | 52.22% |
| 2005 | -31.75 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 92.11 Million CNY | 1208.74% |
| 2024 Q1 | 7.03 Million CNY | -49.73% |
| 2023 Q1 | 27.61 Million CNY | -50.43% |
| 2023 Q2 | 55.92 Million CNY | 102.55% |
| 2023 FY | - CNY | -10.56% |
| 2023 Q3 | 34.94 Million CNY | -37.52% |
| 2023 Q4 | -4.06 Million CNY | -111.64% |
| 2022 Q2 | -50.81 Million CNY | -663.21% |
| 2022 Q4 | 55.69 Million CNY | -37.47% |
| 2022 FY | - CNY | -23.06% |
| 2022 Q3 | 89.07 Million CNY | 275.29% |
| 2022 Q1 | 9.02 Million CNY | -88.02% |
| 2021 FY | - CNY | 12.54% |
| 2021 Q1 | 8.85 Million CNY | -88.9% |
| 2021 Q2 | 67.07 Million CNY | 657.77% |
| 2021 Q3 | 62.25 Million CNY | -7.19% |
| 2021 Q4 | 75.3 Million CNY | 20.96% |
| 2020 FY | - CNY | -29.35% |
| 2020 Q3 | 71 Million CNY | 68.29% |
| 2020 Q2 | 42.19 Million CNY | 645.55% |
| 2020 Q1 | -7.73 Million CNY | -105.65% |
| 2020 Q4 | 79.78 Million CNY | 12.36% |
| 2019 Q2 | 108.39 Million CNY | 639.81% |
| 2019 Q1 | 14.65 Million CNY | -56.8% |
| 2019 Q4 | 136.77 Million CNY | 305.26% |
| 2019 FY | - CNY | 57.49% |
| 2019 Q3 | 33.74 Million CNY | -68.86% |
| 2018 Q4 | 33.91 Million CNY | 0.0% |
| 2018 FY | - CNY | 70.87% |
| 2018 Q2 | 36.9 Million CNY | 0.0% |
| 2018 Q3 | 33.91 Million CNY | -8.1% |
| 2018 Q1 | 36.9 Million CNY | 105.24% |
| 2017 Q3 | 17.98 Million CNY | -47.89% |
| 2017 Q4 | 17.98 Million CNY | 0.0% |
| 2017 Q2 | 34.5 Million CNY | 0.0% |
| 2017 Q1 | 34.5 Million CNY | -40.11% |
| 2017 FY | - CNY | -35.92% |
| 2016 Q3 | 57.61 Million CNY | 95.77% |
| 2016 Q2 | 29.43 Million CNY | 0.0% |
| 2016 Q1 | 29.43 Million CNY | -47.76% |
| 2016 FY | - CNY | 2.1% |
| 2016 Q4 | 57.61 Million CNY | 0.0% |
| 2015 FY | - CNY | 17.23% |
| 2015 Q4 | 56.33 Million CNY | 0.0% |
| 2015 Q2 | 27.92 Million CNY | 0.0% |
| 2015 Q3 | 56.33 Million CNY | 101.74% |
| 2015 Q1 | 27.92 Million CNY | -3.63% |
| 2014 Q3 | 28.97 Million CNY | 20.77% |
| 2014 Q4 | 28.97 Million CNY | 0.0% |
| 2014 FY | - CNY | 29.48% |
| 2014 Q1 | 23.99 Million CNY | -39.87% |
| 2014 Q2 | 23.99 Million CNY | 0.0% |
| 2013 Q2 | 24.33 Million CNY | 150.6% |
| 2013 Q4 | 39.9 Million CNY | 31.13% |
| 2013 FY | - CNY | 63.84% |
| 2013 Q1 | 9.71 Million CNY | -65.53% |
| 2013 Q3 | 30.43 Million CNY | 25.04% |
| 2012 FY | - CNY | 54.98% |
| 2012 Q4 | 28.17 Million CNY | 63.5% |
| 2012 Q3 | 17.23 Million CNY | 28.06% |
| 2012 Q2 | 13.45 Million CNY | 168.72% |
| 2012 Q1 | 5 Million CNY | -86.29% |
| 2011 Q3 | 5.32 Million CNY | 146.0% |
| 2011 FY | - CNY | 220.35% |
| 2011 Q1 | -1.52 Million CNY | -119.13% |
| 2011 Q2 | 2.16 Million CNY | 242.12% |
| 2011 Q4 | 36.52 Million CNY | 586.47% |
| 2010 FY | - CNY | 5692.89% |
| 2010 Q4 | 7.95 Million CNY | 437.7% |
| 2010 Q3 | 1.48 Million CNY | 68.56% |
| 2010 Q2 | 878 Thousand CNY | 125.95% |
| 2010 Q1 | -3.38 Million CNY | 0.0% |
| 2009 Q2 | -2.13 Million CNY | 0.0% |
| 2009 FY | - CNY | 101.63% |
| 2008 FY | - CNY | 27.08% |
| 2007 FY | - CNY | -39.86% |
| 2006 FY | - CNY | 52.22% |
| 2005 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -6.73% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 94.589% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 223.936% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -41.059% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 419.581% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -46.168% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 61.632% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -109.469% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 713.406% |
| SSY Group Limited | 2.11 Billion HKD | 92.409% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 21.463% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 62.662% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 98.96% |